NASHVILLE, Tenn. (July 13, 2016) — NextGxDx Inc. (*now Concert Genetics) today announced an agreement with Oregon Health & Science University (OHSU) to deliver GeneConnect®, the genetic test utilization management solution that enables healthcare institutions to lower the costs and address the workflow inefficiencies associated with genetic test ordering.
“Genetic testing is the key to unlocking the potential of personalized medicine, but the complexity and rapid growth in the field make it difficult to manage,” said Mark Harris, Ph.D., founder and chief innovation officer of NextGxDx. “We’re proud to work with OHSU to deliver the tools they need to manage genetic test ordering in a more systematic and cost-efficient way.”
The laboratory management team at OHSU plans to use GeneConnect’s administrative tools to monitor test utilization, track electronic orders and results, and easily compare testing options across reference labs. By incorporating GeneConnect into their ordering workflow, the goal is to support their physicians and genetic counselors in selecting the most clinically-effective and cost-efficient laboratory tests for their patients.
The agreement between OHSU and NextGxDx begins effective immediately.
Oregon Health & Science University is a nationally prominent research university and Oregon’s only public academic health center. It serves patients throughout the region with a Level 1 trauma center and nationally recognized Doernbecher Children’s Hospital. OHSU operates dental, medical, nursing and pharmacy schools that rank high both in research funding and in meeting the university’s social mission. OHSU’s Knight Cancer Institute helped pioneer personalized medicine through a discovery that identified how to shut down cells that enable cancer to grow without harming healthy ones. OHSU Brain Institute scientists are nationally recognized for discoveries that have led to a better understanding of Alzheimer’s disease and new treatments for Parkinson’s disease, multiple sclerosis and stroke. OHSU’s Casey Eye Institute is a global leader in ophthalmic imaging, and in clinical trials related to eye disease.
*Note: NextGxDx became Concert Genetics in March 2017.